Crizanlizumab 100 mg/10 mL (10 mg/mL) Suppliers & Bulk Manufacturers
Available Forms: IV Infusion
Available Strengths: 100 mg/10 mL (10 mg/mL)
Reference Brands: Adakveo®(EU & US)
Category: Anemia
Crizanlizumab (Adakveo®) is an FDA- and EMA-approved IV biologic for sickle cell disease, available for B2B pharma distribution in the US and EU to reduce pain crises in affected patients.
Product Description:
rizanlizumab (Adakveo®) is a breakthrough biologic therapy for sickle cell disease, available for B2B pharmaceutical distribution across the US and EU markets. It is a humanized monoclonal antibody (anti-P-selectin) used to reduce the frequency of painful vaso-occlusive crises in patients with sickle cell anemia. Approved by the FDA and EMA, Crizanlizumab is supplied as a 100 mg/10 mL IV infusion, ideal for hospital and specialty clinic use. Pharma B2B partners benefit from secure supply chains, regulatory-compliant sourcing, and access to one of the most innovative therapies in hematology. Reliable distribution and market-ready packaging ensure smooth commercialization across regulated markets.
Crizanlizumab — third party manufacturing & bulk supply
Crizanlizumab 100 mg/10 mL (10 mg/mL) is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Crizanlizumab listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Crizanlizumab →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Crizanlizumab is used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease. It helps prevent painful crises by decreasing the adhesion of sickled red blood cells and other blood components to blood vessel walls.
It is made from a humanized monoclonal antibody (IgG2) that targets P-selectin, a cell-adhesion protein involved in vaso-occlusion.
The trade name is Adakveo.
It is manufactured by Novartis.
The generic name is Crizanlizumab-tmca.
The brand name is Adakveo.
It is manufactured in various Novartis production facilities, including sites in Europe and the United States.
Related Products
Mitapivat Sulfate
Strength:
5 mg, 20 mg, 50 mg
Form: Tablets
Reference Brands: Pyrukynd (USA)
View Details
Eltrombopag Cholin 50 Mg Tablet
Strength:
12.5 mg, 25 mg, 50 mg, and 75 mg
Form: Tablets / Oral suspension
Reference Brands: Promacta (USA), Revolade (EU)
View Details
Epoetin Alfa
Strength:
1,000 IU, 2,000 IU, 4,000 IU, 10,000 IU, 40,000 IU
Form: injection (prefilled syringe)
Reference Brands: EPOGEN (USA), PROCRIT (USA)
View DetailsQuick Response Guaranteed | Verified Suppliers
